Key result
Newer generation drug-eluting stents have improved clinical outcomes and lowered the frequency of major cardiac adverse events in diabetic patients undergoing percutaneous coronary intervention.
Why the study?
Does drug-eluting stent implantation improve clinical outcomes in diabetic patients undergoing PCI?
Does drug-eluting stent implantation improve clinical outcomes in diabetic patients undergoing PCI?
This review highlights that newer generation drug-eluting stents have improved clinical outcomes in diabetic patients undergoing PCI, despite diabetes remaining a significant risk factor.
Diabetic population still remains a challenging subgroup of patients for percutaneous coronary intervention (PCI). However, with rapid advancements of PCI techniques, devices and adjunctive drug therapy, clinical outcomes for diabetic patients after PCI have markedly improved. The plethora of recent encouraging data with newer generation drug-eluting stent (DES), with a lower frequency of major cardiac adverse events, lead to an increasing use of DES in this particular high-risk population. However, diabetes remains an important risk factor for coronary events, even in the DES era. This review summarizes the outcomes in diabetic patients undergoing PCI with DES implantation.
No takes yet. Share an insight, caveat, or question.
Bernelli et al. (2013) conducted a review in Diabetes requiring percutaneous coronary intervention. Drug-eluting stent (DES) was evaluated. Newer generation drug-eluting stents have improved clinical outcomes and lowered the frequency of major cardiac adverse events in diabetic patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: